 TOKYO, June 25, 2021 GLOBE NEWSWIRE -- Astellas Pharma Inc. TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas and FibroGen, Inc. Nasdaq: FGEN, CEO: Enrique Conterno, FibroGen today announced the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease CKD.1 CKD impacts one in 10 people globally, of whom one in five are affected by anemia.2, 3 Anemia of CKD is associated with significant impairment in quality of life and progression to adverse cardiovascular CV and renal outcomes.4-6 Anemia of CKD is often untreated or not treated to target.4-6 